Aligned Genetics, Inc. (KOSDAQ:238120)
South Korea · Delayed Price · Currency is KRW 3,205.00
-195.00 (-5.74%)
At close: Jun 8, 2026
Aligned Genetics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 15,735 | 16,016 | 15,778 | 15,215 | 13,753 | 11,762 |
Other Revenue | -0 | -0 | - | -0 | -0 | - |
| 15,735 | 16,016 | 15,778 | 15,215 | 13,753 | 11,762 | |
Revenue Growth (YoY) | -4.69% | 1.51% | 3.70% | 10.63% | 16.92% | 47.82% |
Cost of Revenue | 4,384 | 4,794 | 4,629 | 4,556 | 4,998 | 4,424 |
Gross Profit | 11,351 | 11,221 | 11,148 | 10,659 | 8,755 | 7,338 |
Selling, General & Admin | 6,432 | 6,240 | 5,619 | 5,125 | 4,287 | 3,791 |
Research & Development | 2,285 | 2,017 | 2,292 | 1,684 | 1,079 | 943.58 |
Amortization of Goodwill & Intangibles | 25.42 | 29.13 | 15.7 | 19.3 | 21.33 | 35.46 |
Other Operating Expenses | 109.93 | 105.01 | 96.87 | 84.21 | 77.31 | 59.34 |
Operating Expenses | 9,209 | 8,779 | 8,369 | 7,322 | 5,906 | 5,159 |
Operating Income | 2,142 | 2,443 | 2,780 | 3,337 | 2,849 | 2,179 |
Interest Expense | -161.51 | -103.88 | -169.15 | -214.88 | -165.96 | -28.88 |
Interest & Investment Income | 285.01 | 328.93 | 405.32 | 161.61 | 168.16 | 27.71 |
Currency Exchange Gain (Loss) | 423.35 | 85.02 | 1,530 | 302.06 | 17.89 | 353.05 |
Other Non Operating Income (Expenses) | 64.21 | 34.63 | 33.59 | 8.09 | 83.88 | -238.9 |
EBT Excluding Unusual Items | 2,753 | 2,788 | 4,579 | 3,594 | 2,953 | 2,292 |
Gain (Loss) on Sale of Investments | -566.32 | -178.26 | -36.7 | -147.75 | -510.71 | 1,507 |
Gain (Loss) on Sale of Assets | 10.78 | 10.78 | - | -22.04 | - | 13.94 |
Other Unusual Items | 29.52 | 29.52 | - | - | - | - |
Pretax Income | 2,227 | 2,650 | 4,542 | 3,424 | 2,442 | 3,813 |
Income Tax Expense | -548.16 | -261.79 | 414.26 | 188.16 | 109.5 | -1,729 |
Net Income | 2,775 | 2,911 | 4,128 | 3,236 | 2,333 | 5,542 |
Net Income to Common | 2,775 | 2,911 | 4,128 | 3,236 | 2,333 | 5,542 |
Net Income Growth | -31.57% | -29.47% | 27.57% | 38.72% | -57.90% | 1083.53% |
Shares Outstanding (Basic) | 14 | 14 | 14 | 14 | 14 | 14 |
Shares Outstanding (Diluted) | 14 | 14 | 14 | 14 | 14 | 14 |
Shares Change (YoY) | -2.06% | -1.85% | 0.03% | - | - | 38.26% |
EPS (Basic) | 197.58 | 206.24 | 287.00 | 225.05 | 162.23 | 385.40 |
EPS (Diluted) | 197.58 | 206.24 | 287.00 | 225.00 | 162.00 | 385.40 |
EPS Growth | -30.03% | -28.14% | 27.56% | 38.89% | -57.97% | 756.45% |
Free Cash Flow | -7,698 | -7,459 | 2,808 | 1,970 | 220.98 | -3,171 |
Free Cash Flow Per Share | -548.06 | -528.42 | 195.20 | 137.01 | 15.37 | -220.57 |
Gross Margin | 72.14% | 70.06% | 70.66% | 70.06% | 63.66% | 62.38% |
Operating Margin | 13.61% | 15.25% | 17.62% | 21.93% | 20.72% | 18.52% |
Profit Margin | 17.64% | 18.18% | 26.16% | 21.27% | 16.96% | 47.12% |
Free Cash Flow Margin | -48.92% | -46.58% | 17.79% | 12.95% | 1.61% | -26.96% |
EBITDA | 2,781 | 3,052 | 3,355 | 3,968 | 3,499 | 2,718 |
EBITDA Margin | 17.67% | 19.05% | 21.27% | 26.08% | 25.45% | 23.10% |
D&A For EBITDA | 639.07 | 608.95 | 575.74 | 631.38 | 650.38 | 538.59 |
EBIT | 2,142 | 2,443 | 2,780 | 3,337 | 2,849 | 2,179 |
EBIT Margin | 13.61% | 15.25% | 17.62% | 21.93% | 20.72% | 18.52% |
Effective Tax Rate | - | - | 9.12% | 5.50% | 4.48% | - |
Advertising Expenses | - | 562.03 | 359.22 | 261.67 | 243.86 | 96.94 |